7 afleveringen
Better Education on Glomerulonephritis Annenberg Center for Health Sciences
-
- Gezondheid en fitness
Nephrology experts Jai Radhakrishnan, MD, and Dana Rizk, MD, delve into the complex disease of immunoglobulin A nephropathy (IgAN), addressing unmet treatment needs and novel frontiers of therapy. They discuss IgAN as a chronic disease, reviewing its pathophysiologic basis, morbidity and mortality including significant reductions in health-related quality of life, existing treatment options, and evolving new targeted therapies. The experts review treatment strategies, highlight case studies and share their experience improving long-term health outcomes.
-
-
-
Emerging Therapies: Efficacy and Safety Data from Phase 3 Trials
Phase 3 trials: targeted-release formulation-budesonide, atrasentan, sparsentan, iptacopan narsolimab
Emerging therapies in Phase 2 trials -
IgAN Treatment Strategies
KDIGO Recommendations
Unmet Needs in Clinical Management
Novel Approaches -
Proteinuria in IgAN
Severity as a negative prognostic factor for IgAN
Proteinuria reduction as a treatment goal
Proteinuria reduction as a meaningful secondary endpoint for improved renal outcomes
Proteinuria reduction and ESRD progression -
Diagnosis & Prognosis of IgAN
Clinical Presentation
KDIGO Diagnosis
KDIGO Prognosis
Initial Assessment
Scoring Tools: MEST-C score, International IgAN Prediction Tool